The global demand for AstraZeneca’s Vaxzevria coronavirus vaccine has decreased due to the availability of numerous new vaccines. Despite being widely used globally with over 3 billion doses supplied since its first administration in the UK on January 4, 2021, the company has not generated revenue from the vaccine since April 2023.
The decline in demand for Vaxzevria is attributed to the surplus of updated Covid-19 vaccines that have been developed. As a result, AstraZeneca has made the decision to stop manufacturing and supplying the vaccine. The company has initiated the withdrawal of marketing authorizations for Vaxzevria within Europe, as announced by the European Medicines Agency.
AstraZeneca expressed pride in the role that Vaxzevria played in combating the global pandemic, despite its withdrawal from commercial demand. The situation is still developing and updates will be provided as needed.
Starting on Tuesday, Business Loop 70 in Columbia will be closed for up to 36…
In recent years, airlines have faced increasing competition and pressure to offer unique and memorable…
Yaroslava Mahuchikh from Ukraine set a new world record in high jump during a Diamond…
At the Paris Diamond League, Laura Muir broke the British 1500m record with a time…
Pearl Jam returned to the stage in Barcelona on Saturday night, after postponing three shows…
Carlos Alcaraz is one step closer to defending his Wimbledon title after a tough win…